Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
– Conference Call Today at 8:30 a.m. ET –
ATLANTA, Nov. 13, 2023 (GLOBE NEWSWIRE) — Virios Therapeutics, Inc. (Nasdaq:VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced financial results for the third quarter ended September 30, 2023.
Related news for (VIRI)
- virios therapeutics, inc. and wex pharmaceuticals, inc. announce business combination to form dogwood therapeutics, inc. (nasdaq: “dwtx”)
- Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID
- Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
- Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023